Nomura India maintained its 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. Cipla anticipates ...

With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,52,80,804 comprising of 80,76,40,402 equity shares of face value Rs 2 each.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Drug major Cipla Ltd is the latest company to declare its schedule for the release of its earnings report for the fourth ...

Elara had already factored in approximately $20 million in revenue from gAbraxane in the US for FY26. While 3–4 generic ...

Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., and Cipla Ltd. share prices dragged the NSE Nifty Pharma index ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

During the year, the Generics Business Undertaking of the Company was transferred to Cipla Pharma and Life Sciences Limited (CPLS), wholly owned subsidiary, on a slump sale basis as a going ...

Cipla receives USFDA approval for generic protein-bound paclitaxel, a cancer treatment drug, expected to launch soon.

Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...